《大行報告》匯豐研究上調綠葉製藥(02186.HK)目標價至6.7元 評級「買入」
匯豐環球研究發表報告,下調綠葉製藥(02186.HK)今明兩年收入預測分別17%及10%,每股盈利預測則分別調低56%及52%,以反映收購四種博安導致支出增加、力扑素(Lipusu)於國家醫保藥品目錄降價,及配股令股權出現9%的稀釋。
該行預期集團去年業績遜預期,但認為明年公司可有轉捩點,因血脂康(Xuezhikang)及其他新藥有望推動增長,而力扑素明年亦料可回復增長。
匯豐研究上調綠葉製藥股份目標價,由4.6元升至6.7元,評級維持「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.